<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79098">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02126046</url>
  </required_header>
  <id_info>
    <org_study_id>NFTM20130101</org_study_id>
    <nct_id>NCT02126046</nct_id>
  </id_info>
  <brief_title>Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allo-hematopoietic stem cell transplantation(HSCT) is the only way to cure β-thalassemia
      major at present. To expand donor pool，we developed a haplo-identical HSCT (Hi-HSCT)
      platform. But in prior Hi-HSCT using high dose post-transplant Cyclophosphamide in patients
      with leukemia, cytopenia post-transplant often developed, which was considered as a symptom
      of GVHD. Therefore, the investigators add unrelated umbilical cord blood (UCB) to the
      Hi-HSCT. It has reported that, as third-party cells, UCB will reduce GVHD.The purpose of
      this study is to determine whether unrelated UCB following Hi-HSCT can improve outcomes of
      Hi-HSCT in patients with β-thalassemia major.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>overall survival（OS）</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the measure is a composite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TM-free survival（TFS）</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the measure is a composite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant Related Martality (TRM)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the measure is a composite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary or Secondary Graft Rejection (GR)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the measure is a composite</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The cumulative incidences of acute graft-versus-host disease（GVHD）</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the measure is a composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative incidences of chronic graft vesus host disease (cGVHD)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the measure is a composite</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>Hi-HSC-CBT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>unrelated CB following haplo-identical hematopoietic stem cells transplantation</intervention_name>
    <arm_group_label>Hi-HSC-CBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  β-thalassemia major

          -  &lt; 18 year old

          -  Unrelated umbilical cord blood following Haplo-identical HSCT

        Exclusion Criteria:

          -  ≥ 18 year old

          -  HLA- matched related donors

          -  Unrelated donor transplants

          -  Unrelated umbilical cord blood transplants

          -  Severe  iron overload in heart by T2*
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunfu Li, professor</last_name>
    <phone>+86 20 61641921</phone>
    <email>chunfugzcn@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhiyong Peng, Doctor</last_name>
    <phone>+86 20 61641925</phone>
    <email>pengzhiyong8@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of paediatrics，Nangfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunfu Li, professor</last_name>
      <phone>+86 20-61641921</phone>
      <email>chunfugzcn@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.fimmu.com/english/index.html</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 27, 2014</lastchanged_date>
  <firstreceived_date>April 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Chunfu Li</investigator_full_name>
    <investigator_title>Director and professor</investigator_title>
  </responsible_party>
  <keyword>Cord Blood Transplant</keyword>
  <keyword>Haploidentical HSCT</keyword>
  <keyword>Thalassemia major</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Beta-Thalassemia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
